Feng Chi Biotech (ROCO:6744) Debt-to-Asset : 0.04 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Feng Chi Biotech Debt-to-Asset?

Feng Chi Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$2.6 Mil. Feng Chi Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$8.1 Mil. Feng Chi Biotech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was NT$301.0 Mil. Feng Chi Biotech's debt to asset for the quarter that ended in Dec. 2023 was 0.04.

Feng Chi Biotech Debt-to-Asset Historical Data

The historical data trend for Feng Chi Biotech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Feng Chi Biotech Debt-to-Asset Chart

Feng Chi Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.02

0.01

0.04

Feng Chi Biotech Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial									0.01	-	0.04	0.04	0.04

Competitive Comparison of Feng Chi Biotech's Debt-to-Asset

For the Biotechnology subindustry, Feng Chi Biotech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Feng Chi Biotech's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Feng Chi Biotech's Debt-to-Asset falls into.

Feng Chi Biotech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Feng Chi Biotech's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.649	+	8.149)	/	301.032
	=	0.04

Feng Chi Biotech's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.649	+	8.149)	/	301.032
	=	0.04

Feng Chi Biotech (ROCO:6744) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Feng Chi Biotech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Feng Chi Biotech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Feng Chi Biotech (ROCO:6744) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Feng Chi Biotech Corp (ROCO:6744) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 5, Shaoxing North Street, 5th Floor-1, Zhongzheng District, Taipei City, TWN, 100

Website

http://www.fcbiotech.com.tw

Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.

Feng Chi Biotech (ROCO:6744) Headlines

No Headlines